OIT3 and hepatocellular carcinoma: In addition, HCC patients with higher OIT3 expression levels had better overall survival rates (OS, 8-year survival rates, OIT3-high group: 60.3% vs. OIT3-low group: 35.5%) and disease-free survival rates (DFS, 4-year survival rates, OIT3-high group: 64.9% vs. OIT3-low group: 33.4%) (Figures 3C, D).